ARASENS Phase-3 Clinical Trial: of triple combination ADT+ Darolutamide & Docetaxel showed 32% reduction in risk of death in high volume & high risk mHSPC.
PROpel Phase-3 Clinical Trial: of Olaparib plus Abiraterone vs. Placebo in 1st line mCRPC showed significant improvement in PFS compared to Abiraterone alone.
Magnitude Phase-3 Clinical Trial: in patients with mCRPC with BRCA1/2 mutation treated with Abiraterone + Prednisone + Niraparib has 27% reduction in risk of death compared to patients receiving only Abiraterone + Prednisone
PRESIDE Phase3b Clinical Trial: studied the efficacy and safety of continuing Enzalutamide in chemotherapy naïve mCRPC patients treated with Docetaxel & Prednisolone who have progressed on Enzalutamide
Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
